5-års totaloverlevelse for plateepitelkarsinom
Basert på FIGO stadium (Beller et al., 2006; FIGO (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer, 2006):
| Stadium I | 90 % | (Ia 98 %, Ib 88 %) |
| Stadium II | 81 % |
|
| Stadium III | 68 % |
|
| Stadium IV | 20 % |
|
| Residiv | 25–35 % |
|
5-års overlevelse for ikke-plateepitel vulvacancer
- Bartholini cancer 64,5 % (Beller et al., 2006; FIGO (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer, 2006)
- Melanom 61,9 %
- Adenokarsinom 32,5 %